Anixa Biosciences, Inc.

NasdaqCM:ANIX Rapporto sulle azioni

Cap. di mercato: US$103.0m

Anixa Biosciences Crescita futura

Future criteri di controllo 0/6

Si prevede che Anixa Biosciences aumenterà gli utili e i ricavi rispettivamente del 9.5% e 75.2% all'anno, mentre si prevede che l'EPS crescerà del 24.4% all'anno.

Informazioni chiave

9.5%

Tasso di crescita degli utili

24.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.3%
Tasso di crescita dei ricavi75.2%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento19 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Sep 12
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

May 23
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Jan 19
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ANIX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
10/31/2027N/A-17-16-161
10/31/2026N/A-16-16-161
10/31/2025N/A-15-15-152
10/31/2024N/A-13-46-112
7/31/2024N/A-12-8-8N/A
4/30/2024N/A-12-7-7N/A
1/31/20240-11-7-7N/A
10/31/20230-10-6-6N/A
7/31/20230-11-6-6N/A
4/30/20230-11-6-6N/A
1/31/2023N/A-12-7-7N/A
10/31/2022N/A-14-6-6N/A
7/31/20220-14-6-6N/A
4/30/20220-16-6-6N/A
1/31/20220-15-5-5N/A
10/31/20211-13-5-5N/A
7/31/20211-11-5-5N/A
4/30/20211-9-5-5N/A
1/31/20211-10-5-5N/A
10/31/2020N/A-10-6-6N/A
7/31/2020N/A-10-6-6N/A
4/30/2020N/A-9-5-5N/A
1/31/20200-9-6-5N/A
10/31/20190-12-5-5N/A
7/31/20190-15-5-4N/A
4/30/20191-18-5-5N/A
1/31/20191-17-4-4N/A
10/31/20181-14-4-4N/A
7/31/20181-10-4-4N/A
4/30/20181-7N/A-4N/A
1/31/20180-5N/A-4N/A
10/31/20170-7N/A-4N/A
7/31/20171-6N/A-4N/A
4/30/20170-6N/A-3N/A
1/31/20170-7N/A-4N/A
10/31/20160-5N/A-3N/A
7/31/20160-5N/A-4N/A
4/30/20160-6N/A-3N/A
1/31/20160-7N/A-4N/A
10/31/20150-1N/A1N/A
7/31/20152-3N/A2N/A
4/30/20153-1N/A2N/A
1/31/20154-2N/A3N/A
10/31/20144-10N/A-2N/A
7/31/20143-9N/A-3N/A
4/30/20141-12N/A-3N/A
1/31/20140-12N/A-3N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ANIX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ANIX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ANIX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che ANIX non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che ANIX non avrà alcun fatturato il prossimo anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ANIX è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita